Skip to main content
SpringerLink
Log in

NICE recommends dimethyl fumarate for MS . . .

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. see PharmacoEconomics & Outcomes News 697 p10; 801085800

  2. see PharmacoEconomics & Outcomes News 698 p11; 801085802

References

  1. NICE. NICE recommends new treatment option for multiple sclerosis (Dimethyl fumarate). Media Release : 27 Aug 2014. Available from: URL: http://www.nice.org.uk

  2. NICE. More information needed on type 2 diabetes drug empagliflozin. Media Release : 28 Aug 2014. Available from: URL: http://www.nice.org.uk

  3. NICE. NICE draft guidance recommends eculizumab (Soliris) for treatment of very rare life-threatening blood disorder. Media Release : 3 Sep 2014. Available from: URL: http://www.nice.org.uk

  4. NICE. The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance. Media Release : 8 Sep 2014. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE recommends dimethyl fumarate for MS . . .. PharmacoEcon Outcomes News 711, 36 (2014). https://doi.org/10.1007/s40274-014-1545-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1545-0

Search

Navigation